5 January 2017 -  NICE is appraising certolizumab pegol and secukinumab for psoriatic arthritis.

Certolizumab pegol alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if:

• it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
  
• the person has had a TNF-alpha inhibitor but their disease has stopped responding after the first 12 weeks.
  

Certolizumab pegol is only recommended if the company provides it agreed in the patient access scheme.

Secukinumab alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if:

• it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
  
• the person has had a TNF-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or
  
• TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
  

Secukinumab is only recommended if the company provides it with the discount agreed in the patient access scheme.

Read NICE appraisal consultation document